DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
The largest compounded-semaglutide seller is moving existing patients to FDA-approved medicines.
Hims & Hers said on March 9, 2026 that it will no longer advertise compounded GLP-1 offerings, will move existing patients to FDA-approved medicines, and will offer compounded GLP-1s only when a provider finds them clinically necessary. Hims had launched compounded GLP-1 injections in May 2024 at $199/month. If you are on a compounded product from any telehealth, ask your provider what your transition plan is.